2 covid vaccines show 'promising immune response' in human trials

London, Jun 4: Meghan, Britain's Duchess of Sussex, has spoken about events following the death of George Floyd saying she was sorry that children had to grow up in a world where racism still existed and that current events in the United States were "devastating".

"I know you know that black lives matter," Meghan said in a video she recorded for students graduating from her old high school in Los Angeles which was aired on Wednesday.

The death of Floyd has become the latest flashpoint for long-simmering rage over police brutality against African Americans and led to nationwide protests, some violent, with curfews imposed in some cities to quell the disorder.

"For the past couple of weeks I've been planning on saying a few words to you for your graduation and as we've all seen over the last week what is happening in our country, and in our state and in our home town of LA is absolutely devastating," said Meghan, whose mother is African American and father is white.

"First thing I want to say to you is that I'm sorry, I'm so sorry that you have to grow up in a world where this is still present," she said in her message to the girls at the Immaculate Heart High School.

The duchess, a former US actress and wife of Queen Elizabeth's grandson Prince Harry, said she wanted to say "the right thing" and was nervous her words would be "picked apart".

"The only wrong thing to say is to say nothing. Because George Floyd's life mattered, and Breonna Taylor's life mattered, and Philando Castile's life mattered and Tamir Rice's life mattered and so did so many other people whose names we know, and whose names we do not know," she said.

Britain's royal family by tradition does not comment on political issues. However, Meghan and Harry stepped down from their official royal roles at the end of March and are now living in Los Angeles with their baby son Archie.

In her message, the 38-year-old reflected on her own memories of the 1992 LA riots.

"Those memories don't go away and I can't imagine that at 17 or 18 years old, which is how old you are now, that you would have to have a different version of that same type of experience," she said.

"That's something you should have an understanding of, but an understanding of as a history lesson not as your reality. So I'm sorry that in a way we have not gotten the world to the place you deserve it to be."

Islamabad, Jul 3: The US embassy here in a statement on Friday said the Trump administration through the US Agency for International Development (USAID) “donated a shipment of 100 brand-new, state-of-the-art ventilators” to Pakistan.

The ventilators arrived in Karachi on July 2 and will be sent to hospitals across Pakistan.

“This donation delivers on President Donald Trump’s generous offer of these critically-needed supplies and supports Pakistan’s urgent response to the pandemic,” the embassy said.

Made in America, the ventilators are valued at about $3 million and reflect the latest in cutting-edge medical design and technology, it said.

They are compact, easily deployable, and will enable Pakistan to more effectively treat patients suffering from Covid-19.

The US-Pakistan health partnership to curb the spread of the novel coronavirus is helping to improve and expand laboratory testing, disease monitoring, case tracking, infection prevention and control and patient care, the embassy said.

The US has contributed nearly $27 million in new funding so far to this vital partnership that is growing every day. "We are also thankful for Pakistan's contribution of medical supplies to help fight coronavirus in the US," the embassy said in the statement.

Ambassador Paul Jones said, “The US stands with Pakistan in its fight against the coronavirus. These American-made ventilators will help Pakistani patients in the most acute need of medical care."

The announcement comes days after Pakistan said it had started producing locally designed ventilators.

Pakistan reported 78 more deaths from the coronavirus in the past 24 hours, raising virus-related fatalities to 4,551 while the total number of confirmed cases has increased to 221,896.

On Friday, the health authorities said 1,13,623 persons have recovered from the coronavirus, surpassing the number of active Covid-19 infections in the country for the first time.

Melbourne, Apr 10: Scientists have identified six drug candidates from more than 10,000 compounds that may help treat COVID-19.

The research, published in the journal Nature, tested the efficacy of approved drugs, drug candidates in clinical trials and other compounds.

"Currently there are no targeted therapeutics or effective treatment options for COVID-19," said Professor Luke Guddat from the University of Queensland in Australia.

"In order to rapidly discover lead compounds for clinical use, we initiated a programme of high-throughput drug screening, both in laboratories and also using the latest computer software to predict how different drugs bind to the virus," Guddat said.

The project targeted the main COVID-19 virus enzyme, known as the main protease or Mpro, which plays a pivotal role in mediating viral replication, the researchers said.

This makes it an attractive drug target for this virus, and as people don't naturally have this enzyme, compounds that target it are likely to have low toxicity, they said.

"We add the drugs directly to the enzyme or to cell cultures growing the virus and assess how much of each compound is required to stop the enzyme from working or to kill the virus. If the amount is small, then we have a promising compound for further studies," said Guddat.

After assaying thousands of drugs, researchers found of the six that appear to be effective in inhibiting the enzyme, one is of particular interest.

"We're particularly looking at several leads that have been subjected to clinical trials including for the prevention and treatment of various disorders such as cardiovascular diseases, arthritis, stroke, atherosclerosis and cancer," Guddat said.

Researchers said compounds that are already along the pipeline to drug discovery are preferred, as they can be further tested as antivirals at an accelerated rate compared to new drug leads that would have to go through this process from scratch.

"With continued and up-scaled efforts we are optimistic that new candidates can enter the COVID-19 drug discovery pipeline in the near future," Guddat said.